The efficacy and safety of synthetic CLDN 18.2 PD1/CD28 CAR-T cells in patients with advanced gastric cancer should be validated in future studies using patient-derived xenograft models and clinical trials. The gene discussed is PDCD1; the disease is gastric cancer.